Buffer (1)Kits (2)
Launched (3)
- (3)
- (3)
- (3)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
ABK-002 | - | - | Chemiluminescent Substrate Solution (HRP Marker) | |||
ALK-A005 | - | - | HRP Antibody Labeling Kit (100ug/Reaction) | |||
ALK-A006 | - | - | HRP Antibody Labeling Kit (1mg/Reaction) |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Galunisertib | LY-2157299 | Phase 2 Clinical | Eli Lilly And Company | Breast Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Glioma; Peritoneal Neoplasms; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Solid tumours; Neoplasms; Myelodysplastic Syndromes; Glioblastoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Liver Neoplasms | Details |
| GF-101 | GFH-018; GF-101; GFH018 | Phase 2 Clinical | Genfleet Therapeutics (Shanghai) Inc | Solid tumours; Liver Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung | Details |
| ORG-129 | ORG-129; AGMB-129 | Phase 2 Clinical | Origo Biopharma Sociedad Litmitada | Crohn Disease | Details |
| TRK-250 | TRK-250; BNC-1021 | Phase 1 Clinical | Bonac Corp | Idiopathic Pulmonary Fibrosis | Details |
| Itacnosertib | TP-0184 | Phase 1 Clinical | Tolero Pharmaceuticals Inc, Sumitomo Dainippon | Solid tumours; Anemia | Details |
| Oxinseti | SH-3051 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Solid tumours; Liver Neoplasms | Details |
| AGMB-447 | AGMB-447; ORG-447 | Phase 1 Clinical | AgomAb Therapeutics NV | Idiopathic Pulmonary Fibrosis | Details |
| TD-1058 | Phase 1 Clinical | Theravance Biopharma Inc | Idiopathic Pulmonary Fibrosis | Details |




